Yaoyuan Tan has been making significant contributions to Vertex Pharmaceuticals as a Senior Biostatistician II since January 2020. In this pivotal role, Yaoyuan serves as the Study Biostatistician for several critical clinical trials, including an Open Label Extension Study, a Double Blind Randomized Controlled Trial...
Yaoyuan Tan has been making significant contributions to Vertex Pharmaceuticals as a Senior Biostatistician II since January 2020. In this pivotal role, Yaoyuan serves as the Study Biostatistician for several critical clinical trials, including an Open Label Extension Study, a Double Blind Randomized Controlled Trial (RCT), and a Phase 1/2 study focusing on Cystic Fibrosis (CF) and Type 1 Diabetes (T1D). His expertise in biostatistics is instrumental in ensuring the integrity and validity of clinical data, which ultimately drives the development of innovative therapies.
Yaoyuan's responsibilities encompass a wide range of activities that are vital to the successful execution of clinical studies. He collaborates closely with the Study Execution Team (SET) to develop essential documents such as study protocols, Case Report Forms (CRFs), and Clinical Study Reports (CSRs). His proficiency in statistical programming languages, including SAS and R, allows him to author comprehensive Statistical Analysis Plans (SAP) and create Table, Figure, and Listing (TFL) shells that effectively communicate complex data insights.
In addition to his technical skills, Yaoyuan plays a key role in cross-functional data reviews (xFDR) and the preparation of Key Results Memos (KRM), ensuring that critical findings are disseminated accurately and efficiently. His background in causal inference and mediation analysis enhances his ability to draw meaningful conclusions from data, contributing to the overall success of Vertex's clinical programs. As he continues to expand his knowledge and expertise, Yaoyuan remains committed to leveraging his skills in statistical modeling and data analysis to advance the field of biopharmaceutical research and improve patient outcomes.
